Gubra raised earnings guidance for full-year 2023. Organic revenue growth to be 25-28% compared to previous guidance of 16-21%. EBIT-margin excl.
special items to be 26-28% compared to previous guidance of Around 25%.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
332.5 DKK | +1.99% | +1.82% | +168.00% |
07/05 | Gubra A/S Announces Management Changes | CI |
17/04 | Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss | CI |
Gubra raised earnings guidance for full-year 2023. Organic revenue growth to be 25-28% compared to previous guidance of 16-21%. EBIT-margin excl.
special items to be 26-28% compared to previous guidance of Around 25%.
1st Jan change | Capi. | |
---|---|---|
+168.00% | 774M | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+4.60% | 22.67B | |
-9.79% | 18.14B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+1.46% | 13.45B | |
+24.22% | 11.32B |